Psoriasis Mouse Model (IL-23 Induced)
Perform quick efficacy tests to evaluate your novel psoriasis treatment strategies using the acute psoriasis mouse model
Psoriasis Mouse Model Key Characteristics
Preclinical psoriasis mouse models are essential tools for understanding the pathogenesis of psoriasis and evaluating the efficacy of novel therapeutic approaches ranging from topical to systemic treatments. Acute models, such as the IL-23 and Imiquimod-induced models, rapidly induce psoriasis-like symptoms, while chronic models mimic the long-term progression of the disease.
The acute psoriasis model, created by intradermal ear injections of recombinant IL-23, leads to acute skin inflammation. IL-23, a key cytokine, promotes pathogenic lymphocytes that drive keratinocyte differentiation and inflammation, hallmarks of psoriasis. This model mimics human psoriasis features, such as inflammatory cell infiltration, epidermal hyperplasia, and activation of inflammatory pathways.
✓ Rapid induction of psoriasis-like symptoms.
✓ Phenotype exhibits key psoriasis hallmarks, including inflammatory cell infiltration and epidermal hyperplasia.
✓ Suitable for testing IL-23 inhibitors and other modulators of the IL-23-induced inflammation pathway.
As a preclinical immunology CRO, InnoSer offers relevant expertise to support various skin inflammation studies including psoriasis, atopic dermatitis, contact dermatitis, and scleroderma research. In accordance, our dermatological platform allows us to investigate the efficacy of your novel investigational compound(s) in similar models, including Imiquimod-induced psoriasis, Ovalbumin or Oxazole-induced atopic dermatitis, and the Bleomycin-induced scleroderma model.
Take advantage of InnoSer’s collaborative approach to develop the most optimal study design. With flexible and fast study start times you can perform your research at an accelerated pace. By outsourcing your preclinical oncology studies to InnoSer, you gain access to our in vitro and in vivo immunology drug development portfolio.
Psoriasis Mouse Model Sample Data
The IL-23 induced psoriasis mouse model represents a translationally relevant model of psoriasis, while allowing you to obtain quick efficacy data.
8-weeks old C57BL6/J mice were injected with recombinant IL-23 in right ear and with PBS (serving as within-subject control) in left ear every two days for a total of 8 days. Mice were dosed with vehicle, test treatment and positive control twice daily via oral gavage. Ear thickness increased in the IL-23 control (vehicle) group following IL-23 injection. A slight decrease in ear thickness was observed on days 4 and 6 in the positive control-treated group.
The IL-23 induced psoriasis mouse model represents a translationally relevant model of psoriasis, while allowing you to obtain quick efficacy data.
Scoring of psoriasis-like lesions following histopathology assessment reveals increase in inflammatory cell infiltration and hypergranulosis in response to IL-23 treatment. Score 0 indicates presence of such features in normal limits, while scores 2 and 3 indicate slight to moderate presence of psoriasis-like features in the tissue. Bars represent M ± SD.
The IL-23 induced psoriasis mouse model represents a translationally relevant model of psoriasis, while allowing you to obtain quick efficacy data.
H&E-stained sections of ear skin confirm psoriasis-like lesions in the IL-23 induced psoriasis mouse model. Vehicle-treated ear sections show spongiosis.
Key IL-23 Induced Mouse Model Readouts
The People Behind Your Research
Céline Erens, PhD, Immunology Study Director
An expert team led by our immunology study director; Céline Erens works together with you to help you set up optimal study designs. Curating the preclinical testing of your lead compounds with a deep understanding of the field is your solution to accelerating your drug development.
Yanick Fanton, PhD, Chief Scientific Officer
As Chief Science Officer at InnoSer, Yanick is responsible for all customer studies at InnoSer and takes care of the scientific and technical coordination.
Discover Other Related Immunology Mouse Models
Stay Curious: More Articles to Explore
Pancreatic Cancer PDX Models
Last month, November, represented Pancreatic Cancer Awareness Month; a time to focus on the challenges posed by one of the most aggressive and lethal cancer types. Pancreatic cancer accounts for approximately 3% of all diagnosed cancers in Europe, with pancreatic...
Exploring InnoSer’s Key In vitro Oncology Services: PD-1 PD-L1 Blockade Assay
Immune Checkpoint Blockade in Oncology Drug Discovery In recent years, immune checkpoint blockade has emerged as a groundbreaking therapeutic strategy in immuno-oncology. Programmed cell death 1 receptor (PD-1), and its ligand programmed cell death ligand 1 (PD-L1)...
RENCA Mouse Mouse Model of Renal Cancer
Approximately 400,000 people are diagnosed with kidney cancer annually. Kidney tumors are classified into different subtypes based on the cell of origin. Over 85% of malignant renal cell tumors are RCC, with the other 15% being nephroblastic, mesenchymal and...
Tumor microenvironment (TME) multiplex immunophenotyping analyses
The use of preclinical orthotopic tumors to better recapitulate the tumor microenvironment (TME) Complex interactions between the cellular and structural components of the tumor microenvironment (TME) composed of tumor cells, fibroblasts, endothelial cells, immune...
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
Animal Welfare
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
info@innoserlaboratories.com